Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | FABP3 | P05413 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.49 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775743 | 0.90 | SCN9A (0.57) | NPC1GLRA1L3MBTL1MEN1KMT2A | |
| SCHEMBL514323 | 0.88 | L3MBTL1 (0.50) | SGMS2PTGER1NPC1GLRA1L3MBTL1 | |
| SCHEMBL1305739 | 0.87 | PTGER1 (0.61) | SGMS2PTGER1NPC1HTTFABP3 | |
| SCHEMBL341109 | 0.87 | SGMS2 (0.62) | SGMS2PTGER1NPC1HTTGAA | |
| SCHEMBL16789583 | 0.85 | GLRA1 (0.55) | SGMS2GLRA1L3MBTL1MAPTTDP1 | |
| SCHEMBL7689222 | 0.84 | SGMS2 (0.52) | SGMS2PTGER1NPC1HTTGAA | |
| SCHEMBL7689226 | 0.84 | PARP1 (0.61) | SGMS2PTGER1NPC1HTTGAA | |
| SCHEMBL28181099 | 0.84 | CHRM4 (0.53) | SGMS2PTGER1NPC1HTTGAA | |
| SCHEMBL8489879 | 0.84 | MAPT (0.57) | SGMS2PTGER1NPC1HTTGAA | |
| SCHEMBL20456203 | 0.84 | RXRA (0.42) | SGMS2PTGER1NPC1HTTGLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4290532-A2 | SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION | The Regents of the University of California (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3520117-B1 | SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION | UNIV CALIFORNIA (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11235076-B2 | Chelating platform for delivery of radionuclides | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-02-01 | — | — | US | disclosed |
| US-11149046-B2 | Antibacterial sideromycins | Hsiri Therapeutics, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210009510-A1 | CHELATING MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-20190287691-A1 | SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-09-19 | — | — | US | disclosed |
| US-20190184041-A1 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | Hsiri Therapeutics, LLC | 2019-05-23 | — | — | US | disclosed |
| WO-2018063638-A1 | CHELATING MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018044812-A2 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| US-6380181-B1 | AMINO ACID RESIDUES IN THE 3-AND/OR 4-POSITION FUNCTION AS SIDEROPHORES AND/OR AS BIOLOGICAL CHELATING AGENTS FOR IRON IN GRAM-NEGATIVE BACTERIA | GRUENENTHAL GMBH (DE) | 2002-04-30 | — | — | US | disclosed |
| EP-0907633-B1 | NEW SYNTHETIC CATECHOL DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | GRUENENTHAL GMBH (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0241915-B1 | METHOD FOR DETERMINING CHOLINESTERASE ACTIVITY | NITTO BOSEKI CO., LTD. (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-4861713-A | Novel method for determining cholinesterase activity | NITTO BOSEKI CO., LTD. (JP) | 1989-08-29 | — | — | US | disclosed |
| EP-0241915-A1 | Method for determining cholinesterase activity | NITTO BOSEKI CO., LTD. (JP) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190184041-A1 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | SLC40A1, TFRC, SLC39A14 | SGMS2 2311/4885PTGER1 3714/4885NPC1 664/4885 |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | SGMS2 1584/4885PTGER1 592/4885NPC1 1549/4885 |
| US-20190287691-A1 | SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION | SLC39A14, SLC39A11, SLC39A7 | SGMS2 3817/4885PTGER1 4828/4885NPC1 2967/4885 |
| US-11235076-B2 | Chelating platform for delivery of radionuclides | SLC40A1, TFRC, SLC39A14 | SGMS2 2311/4885PTGER1 3714/4885NPC1 664/4885 |
| US-20210009510-A1 | CHELATING MOLECULES | SLC39A3, SLC30A6, SLC30A7 | SGMS2 678/4885PTGER1 4404/4885NPC1 1603/4885 |
| US-11149046-B2 | Antibacterial sideromycins | SLC40A1, SFXN1, SLC39A14 | SGMS2 737/4885PTGER1 4537/4885NPC1 2148/4885 |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | SLC40A1, SFXN1, SLC39A14 | SGMS2 737/4885PTGER1 4537/4885NPC1 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.